PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Expert Rev Endocrinol Metab. Author manuscript; available in PMC 2010 July 1.
Published in final edited form as:
Expert Rev Endocrinol Metab. 2009 July 1; 4(4): 359–370.
doi:  10.1586/eem.09.16
PMCID: PMC2825701
NIHMSID: NIHMS177412

GENE THERAPY FOR THE TREATMENT OF PITUITARY TUMORS

Abstract

Pituitary adenomas constitute the most frequent neuroendocrine pathology in humans. Current therapies include surgery, radiotherapy and pharmacological approaches. Although useful, none of them offers a permanent cure. Current research efforts to implement gene therapy in pituitary tumors include the treatment of experimental adenomas with adenoviral vector-mediated transfer of the suicide gene for thymidine kinase, which converts the prodrug ganciclovir into a toxic metabolite. In some cases, the suicide transgene has been placed under the control of pituitary cell-type specific promoters. Also, regulatable adenoviral vector systems are being assessed in gene therapy approaches for experimental pituitary tumors. Although the efficiency and safety of current viral vectors must be optimized before clinical use, they remain as highly promising therapeutic tools.

Keywords: gene therapy, viral vectors, pituitary tumors, neurosurgery, suicide gene therapy, combined therapy, IGF-I gene therapy, proapoptotic genes

INTRODUCTION

Pituitary adenomas constitute the most frequent neuroendocrine pathology in humans, comprising up to 15% of primary intracranial tumors [1]. Also, pituitary tumors represent the most prevalent pathology in old female rats [2]. Clinical manifestations of pituitary adenomas arise from overproduction of hormones in microadenomas or from mass effects in larger tumors.

There are six types of hormone-producing pituitary adenomas which reflect the cell type that originated the tumor (Table 1). These tumor types are prolactin (PRL)- and growth hormone (GH)-secreting tumors that cause reproductive abnormalities [3] and the syndromes of acromegaly [4], respectively; corticotropin (ACTH)-producing tumors that cause Cushing’s disease [4] gonadotropin- and thyrotropin-secreting tumors that cause abnormalities in their respective axes and null-cell type adenomas that produce none of the above hormones [5, 6]. Mass effects of enlarging tumors usually include visual field defects resulting from compression of the optic nerves, headaches, hypopituitarism and, rarely, invasion into the skull base causing multiple intracranial nerve palsies. Only exceptionally are pituitary tumors truly malignant with distant metastases [7].

Table 1
Classification of Pituitary Tumors

Current therapies for pituitary tumors include surgery and radiotherapy, as well as pharmacological approaches for some types [6, 8]. Transsphenoidal surgery has proven to be highly effective for microadenomas but not for macroadenomas [9]. In both cases post-surgical complications, like the appearance of a new pituitary dysfunction, diabetes insipidus and sometimes fistula formation, develop even in patients operated on by specialist surgeons [10]. Pharmacological therapies, with dopamine agonists like bromocriptine, cabergoline and quinagolide, have met with remarkable success in shrinking prolactinomas and reducing the hyperprolactinemia associated with them [11]. Unfortunately, a significant rate of side effects like nausea, vomiting, postural hypotension, dizziness, headaches, and constipation is present in long-term treatments with these drugs [12]. In patients with GH-producing adenomas, somatostatin analogues and depot preparations of octreotide can lower the usual hypersomatotropinemia to levels compatible with acceptable long-term survival [13]. Treatment with octreotide of 27 newly diagnosed acromegalic patients for 6 months, followed by treatment with a long-acting octreotide preparation for additional 6 months, resulted in 79% of the patients having mean serum GH levels below 5 mU/liter, 53% having normal IGF-I levels, and 73% of the patients showing greater than 30% tumor shrinkage [14]. None of the aforementioned pharmacological treatments cure the tumors which will usually recur if the medications are discontinued. Radiotherapy is usually used as an adjunctive treatment after pituitary tumor surgery. Although long-term irradiation is often effective to prevent tumor regrowth, it usually causes complications, the most frequent (58 to 83%) of which is hypopituitarism [15]. Other less frequent complications associated with conventional radiotherapy for pituitary adenomas are 2% optic chiasmal injury and 0.2% radiation brain necrosis. Although rare, radiation-induced fibrosarcomas and osteosarcomas have been reported [16]. Focused radiotherapy, either in the form of stereotactic multiarc radiotherapy or gamma-knife that can be applied to a small area, have the advantage to reduce damage to normal pituitary tissue and surrounding vascular and neuronal structures [7, 17].

In summary, although important advances have been made in the treatment of pituitary tumors, a fully satisfactory therapy is not yet available. In this context, gene therapy appears as a potentially useful alternative for the treatment of pituitary tumors. Although research efforts to apply this methodology to the hypophysis are relatively recent, promising experimental results, discussed later in this review, have already emerged.

VIRAL VECTOR-BASED GENE DELIVERY METHODS

Although current gene delivery methods comprise viral and non-viral approaches, use of the latter for gene therapy of pituitary tumors has, to our knowledge, not been documented. Therefore, they will not be discussed. The wide use of recombinant viral vectors as gene delivery systems is due to their high efficiency for gene transfer (Table 2). In the pituitary gland, gene therapy strategies have mainly relied, up to now, on the use of adenovirus-derived vectors, although herpes-derived vectors have also been employed in some studies.

Table 2
Characteristics of different types of viral vectors.*

Adenoviral vectors

Adenovirus(Ad)-derived vectors have been used for both basic and therapeutic applications in the neuroendocrine system. Ads are non-enveloped DNA viruses, with a genome of 36 Kb, which possess the ability to infect a wide variety of dividing and non-dividing cells.

The cellular receptors for Ad are the high affinity receptor called CAR (Coxackie and Adenovirus Receptor), which attaches to the viral fiber knob protein [18] and the avb3/5 integrins which interact with the viral penton base [19]. After endocytosis, the virus escapes from the endosomal compartment to the cytosol and docks onto the nuclear pore complex, where the viral DNA plus some associated proteins are translocated into the nucleus. There, the viral genome remains in a non-integrated (episomal) state. Adenoviral genes have been classified as early genes (which encode regulatory proteins that are expressed before DNA replication) and late genes (expressed after DNA replication and encoding structural proteins). The early E1 gene product is the main trans-activator of adenoviral gene transcription, including those genes needed for viral replication. This genomic region is deleted in adenoviral vectors in order to render them replication-defective and to prevent expression of the viral genome. This E1 genomic region must be complemented in trans (i.e., in a separate DNA) to replicate the vector, which is often done by means of a cell line, like the HEK 293, stably transfected with the deleted viral genes [20]. In some viral vectors other adenoviral genes have been deleted in order both to make more space for cloning exogenous genes and to diminish the immunogenicity and cytotoxicity of the vector. First generation recombinant adenoviral vectors usually lacked E1 and E3 genomic regions, the latter being deleted to make more space for exogenous sequences. However, despite the E1 deletion, some activation of viral gene transcription still occurs, perhaps mediated by cellular proteins with E1-like activity. Viral protein expression elicits a strong immune response, characterized by cytotoxic T lymphocytes (CTL), which eliminates the infected cells [21]. To overcome this limitation,, other genomic regions have been deleted in newer adenoviral vectors. The most promising of these are the so called ‘gutless’ or ‘helper dependent’ adenovectors, HD-Ads, (up to 35 kb of foreign DNA), in which all adenoviral genes are deleted and have only the ends of the adenoviral genome (inverted terminal repeats or ITR, which are necessary for viral DNA replication) and the encapsidation signal. As the vector cannot express any viral protein, generation of gutless vectors requires that all Ad genes be provided in trans, usually by coinfection with an adenovirus, called ‘helper virus’ [22]. Since the helper virus used to generate the gutless vector remains as a contaminant, several systems have been designed to minimize helper titres in gutless viral stocks [23]. With these multiple-deleted vectors, the risk of chance generation of replication-competent viruses is decreased, since several recombination events are required to regenerate a replication-competent Ad.

Adenoviral vectors have several advantages over other vectors (Table 2). 1) As indicated above, Ads can efficiently infect cells in replicative state as well as cells out of the cell cycle; 2) they have a capacity of up to 35 Kb of DNA (in HD-Ads), which in many instances provides enough space for transgene(s) and regulatory sequences; 3) the biology of these viruses is well known, and there is a wide range of adenoviral systems available; 4) Ads are easy to manipulate; 5) the fact that the Ad genome does not integrate into the host genome avoids the risk of insertional mutagenesis. [20].

As mentioned above, the critical limitation of adenoviral vectors comes from the usually strong host’s immune response against the viral particle and the infected cells. This immune response limits the long-term expression of transgenes because CTL kill the infected cells and prevent re-administration of the vector. Current strategies to overcome Ad-induced immune responses include the use of Ad vectors carrying immuno-suppressant genes [24; also see below], administration of immunosuppressant drugs like cyclosporin [25] and oral tolerization to viral antigens [26].

Herpes Simplex Virus type 1 (HSV1)-derived vectors

Another type of vectors that has been used for gene transfer in the pituitary gland corresponds to those derived from the HSV-1. This is a double stranded DNA virus with an envelope derived from the host cell. The virus has 38 genes that are non-essential for the viral cycle and could therefore be deleted thus generating recombinant vectors with sufficient space to clone more than one transgene or regulatory sequences like specific or regulated promoters. HSV-1 can establish two types of infections: a lytic cycle or, in some neurons, a latency state. The lytic cycle is characterized by a cytopathic effect, in part due to the effect of infected cell proteins (ICP), coded for by immediate early (IE) genes. One of these ICP, ICP4, is the main factor implicated in the transition from the immediate early phase to the early phase of the lytic cycle. In the latent state, there is a very low level of viral gene transcription, which results in low levels of latency associated viral RNAs [27].

There are two types of HSV-1-derived vectors: amplicons, which will not be discussed here, and recombinant viruses. In the latter, the transgene(s) is cloned into the HSV-1 genome [for a review see 28]. There are two major types of these, called the first- and second-generation HSV-1-derived vectors. The first-generation vectors have a mutation or deletion in a single essential immediate early (IE) gene. A relevant example of these vectors is the tsK, which is the only type of herpes-derived vector so far used in the pituitary gñand (see below). This vector is a temperature-sensitive (ts) mutant of the HSV-1, which has a point mutation in the IE3 gene that hinders the replication process at 37 °C but not at 31°C. The IE3 gene was chosen because its protein product, ICP4, is the major trans-activator of early genes, and consequently, the expression of viral early and late genes is reduced when IE3 is inactive. The transgenes are cloned into the thymidine kinase (TK) locus under the control of an active HSV-1 IE promoter. Wild type revertants arise with a relatively high frequency during vector preparation and contaminate viral stocks with replication-competent viruses. A negative feature of first-generation herpes-derived vectors is their cytotoxicity, which stems from the fact that they still express toxic viral genes [29]. The second-generation HSV recombinant vectors have deletions in more than one gene, which makes them less cytotoxic. So far, they have not been used in the pituitary gland.

Other Viral Vector Systems

Retroviruses and lentiviruses are RNA viruses which are considered advantageous because they are integrating viruses. The ability to incorporate their DNA into the host allows for the therapeutic gene to be permanently present in the genome of the cells infected and can be passed on to future generations of that cell. Lentiviruses have an additional advantage due to their ability to transduce dividing and nondividing cells [30, 31]. This unique characteristic makes them strong candidates for gene therapy. Unfortunately there are disadvantages that go along with these integrating vectors. The possibility of insertional mutagenesis is a significant concern or integration within an oncogene which could therefore lead to cancer [32, 33]. With lentiviruses, the fear that recombination could lead to HIV infection in gene therapy patients is a drawback, even though the vectors have been constructed in such a way that recombining is a negligible possibility.

EXPERIMENTAL GENE THERAPY IN PITUITARY TUMORS

Reporter gene transfer studies

Initial studies with adenoviral and herpes-derived vectors demonstrated that these two vector systems could be used to efficiently transfer different types of genes into normal rat anterior pituitary (AP) cells in primary culture as well as in the corticotropic AtT20 and somatomammotropic GH3 tumor cell lines [34, 35]. Interestingly, neoplastic AP cells were found to be more susceptible to viral vector-mediated transduction than were normal AP cells. Include also the paper by Windeat et al, Endocrinology, it was the first report of transcriptional targeting and expression in the AP both in vitro and in vivo using the PRL promoter to drive transgene expression encoded within Ad vectors.

Direct stereotaxic injection into the sheep pituitary of Ad vectors carrying the E. coli β-galactosidase ([exists]-gal) gene under the control of either the human PRL (hPRL) or hCMV promoters led to high levels of transgene expression up to 7 days after surgery. Histologic examination of these pituitaries revealed varying degrees of inflammatory response, with periglandular fibrosis, lymphocytic infiltrate and venulitis in almost all cases [36].

Other in vivo studies in rats have shown that intravascular administration of adenoviral vectors, harboring the [exists]-gal gene under the control of the hGH or the glycoprotein hormone ∀-subunit promoters, fail to express the transgene at pituitary level. On the contrary, stereotaxic injection of these vectors into the pituitary of rats succeeded in selectively expressing the transgene in the appropriate AP cell populations [37].

The HSV1-derived vector tsK was shown to be highly effective for in vivo transfer of the [exists]-gal gene in rat pituitary prolactinomas [38, 39].

Human pituitary gonadotroph and somatotroph adenoma cells were transduced in vitro using a human immunodeficiency virus (HIV)-type 1-derived vector encoding the enhanced green fluorescent protein (eGFP) gene under the phosphoglycerate kinase promoter [40].

Suicide gene therapy

Suicide gene therapy has been the more widely used approach to implement gene therapy for pituitary tumors, both in vitro and in vivo.

A recombinant adenoviral (RAd) vector, RAdTK, harboring the HSV-1 thymidine kinase (TK) suicide gene under the control of the human cytomegalovirus (hCMV) promoter, was used to transfer the TK gene to GH3 and AtT20 cells. Incubation of RAdTK-treated GH3 and AtT20 cells with the prodrug ganciclovir (which after phosphorylation by viral TK becomes toxic) caused ample destruction of the cultures [41]. In the same study, estrogen/sulpiride-induced rat prolactinomas were stereotaxically injected with the same RAdTK. Subsequent injection of the host animals with two daily i.p. doses of 25 mg ganciclovir/kg for 7 days succeeded in partially reducing AP tumor size and serum PRL levels. Gene therapy, using adenoviral vectors harboring the TK gene under the control of specific AP hormone promoters, namely the human GH and glycoprotein hormone ∀-subunit promoters, was effective for the treatment of GH3 and ∀-subunit producing pituitary tumor cell lines in vitro, respectively [42]. An adenoviral vector, encoding the TK gene under the control of the hPRL promoter was also effective to induce apoptosis in GH3 cell cultures exposed to ganciclovir. It did not significantly reduce the growth and PRL-secretory rate of estrogen-induced rat prolactinomas in vivo [43]. Adenoviral vectors, harboring the TK gene under both a promiscuous hCMV and the hPRL promoter, showed expression of the transgene for up to 3 months in situ in the normal rat anterior pituitary [44], while nude mice carrying GH3 cell-grafted subcutaneous tumors were effectively treated with an adenoviral vector harboring the TK gene under the control of the hGH promoter [42].

A hybrid cDNA encoding a chimeric protein corresponding to HSV1-TK fused to enhanced GFP which still emits green fluorescense and retains TK suicide activity [45] was cloned into an adenoviral vector, termed RAd-(GFP/TK)fus, which successfully transduced experimental rat pituitary adenomas in vivo [46; Fig. 1]. This vector was also shown to express high fluorescence levels in cultures of the lung tumor cell line A549 and kill these cells when gancyclovir was added to the cultures (Fig. 2).

Figure 1
Expression of transgenic (GFP/TK)fus in a rat pituitary adenoma
Figure 2
Suicide activity of a GFP/TK fusion protein

A GH cell-type specific adenoviral vector was constructed in which a stuffer DNA fragment, flanked by two loxP sequences, was placed between the hGH promoter and the diphtheria toxin gene (GHp-loxP-DT). When the GH-producing cell line GH4 was co-transduced with this vector and with another one harboring the expression cassette for GHp-Cre, rapid destruction of the cultures occurred. Furthermore, subcutaneous GH4 tumors, generated in nude mice, involuted rapidly when topically injected with the above vectors in the tumor area [47].

Incubation of GH3 cells with RAd’s expressing the gene for either tumor necrosis factor-α (TNFα)- or FasL, two pro-apoptotic molecules whose receptors are present on the membrane of lactotropic cells, was shown to increase apoptotic activity in these cells [48]. This study suggests that pro-apoptotic gene therapy may constitute a suitable alternative to TK gene therapy for the treatment of certain types of pituitary tumors, like prolactinamas.

The retinoblastoma mutant mouse

Another type of gene therapy strategy for the treatment of pituitary cancer is that based on the transfer of a gene(s) with the ability to rescue the normal phenotype of tumor cells. This approach has been implemented in mice heterozygous for the retinoblastoma (RB) tumor suppressor gene (Rb+/− mice). Such mice develop and succumb to characteristic pituitary intermediate lobe melanotroph tumors [49]. Transduction of tumor melanotrophic cells with a recombinant adenoviral vector (rAd5.R.Rb) carrying the human RB cDNA under the control of its own promoter, showed a high level of efficiency both in vitro and in vivo [50]. Furthermore, intracranial delivery of this vector to mice carrying actively growing melanotrophic tumors significantly reduced tumor growth and prolonged animal survival. Melanotrophic tumor proliferative index and apoptotic rates were markedly lowered in the rAd5.R.Rb-treated animals, which also showed growth-inhibitory dopaminergic neuron reinnervation of melanotrophic cells. [50].

Insulin-like growth factor I gene therapy

The pituitary gland produces several growth factors [51, 52] that may affect the function and proliferation of pituitary cells through autocrine or paracrine action [53]. One such factor, insulin-like growth factor type I (IGF-I), which is abundant and homogeneously distributed throughout the anterior and intermediate pituitary lobes [54] has shown promise for the treatment of experimental pituitary adenomas. In effect, IGF-I gene therapy was recently reported to induce a partial regression of estrogen-induced prolactinomas in rats [46]. In this type of tumors, IGF-I gene therapy was also reported to normalize the somatotropic cell population and reduce GH secretion which is also elevated in these adenomas [55].

REGULATABLE VECTOR SYSTEMS FOR THE TREATMENT OF PITUITARY TUMORS

Two central objectives in the development of viral vectors are the achievement of cell-type specificity for transgene delivery, and the design of vectors where, once the transgene is incorporated into the target cell, its expression can be regulated by small molecules. Cell-type specificity has already been achieved in pituitary tumor cells by placing transgenes under the control of cell-type specific promoters like the GH, ∀-glycoprotein and PRL promoters for pituitary tumor cells, as noted previously.

Early inducible gene expression systems encountered limitations such as pleiotropic effects of the inducer, basal leakiness, toxicity of inducing agents and a low level of expression. Nevertheless, nontoxic, tightly-regulated control of transgene expression has been achieved with a tetracycline (Tet) gene control system [56]. Two types of Tet gene control system have been devised. A Tet-Off system is one such system. It is composed of a Tet transactivator (a hybrid protein termed tTA, which contains the Tet and DNA binding domains of the E. coli Tet repressor fused to VP16, an HSV-1 transactivator) which binds to E. coli-derived Tet-resistance operon regulatory elements embedded within a minimal CMV promoter (tetO/minCMV). Binding of tTA to this region recruits strong cellular transcription factors thus inducing transcription of a transgene inserted downstream. When Tet is present, it binds to tTA causing the dissociation of tTA from the tetO/minCMV complex thereby inhibiting transgene expression. The second type of gene control system is the Tet-On system. Here tTA is modified by four amino acids giving rise to the rtTA transactivator which, by itself is inactive, but in the presence of the Tet analogue doxycycline (DOX), binds to the tetO/minCMV region and induces high levels of transgene expression.

A number of Tet-regulatable viral systems have now been developed, including a Tet-off dual adenoviral system for the [exists]-gal reporter gene with the DNA sequence encoding the tTA transactivator placed under the control of the hPRL promoter. With this system, specific transgene expression in rodent lactotrophic cells was achieved both in vitro and in vivo. Furthermore, this expression could be turned off by administration of DOX and then back on when the antibiotic was removed [57]. A similar dual regulatable adenoviral vector system, in this case expressing tyrosine hydroxylase (TH) under the control of the hCMV promoter, has been also constructed. As TH is the rate-limiting enzyme for dopamine synthesis, the growth of both lactotrophic cell lines (GH3 and MMQ) and estrogen-induced rat prolactinomas was significantly inhibited when co-transduced with the two vector components of the regulatable TH vector system. The expression of TH could be turned off by DOX, and back on by the removal of the antibiotic [58].

We are currently constructing a bidirectional Tet-Off RAd expressing the gene for (GFP/TK)fus and the gene for an analog of the antiinflammatory peptide, thymulin (Fig. 3). Adenovirally-expressed thymulin displays an exceptional longetvity of expression (for a RAd) in skeletal muscle and in the brain which is believed to be due to its antiinflammatory activity [59, 60; Fig. 4]. Therefore, the above bidirectional vector could allow effective TK suicide pituitary tumor gene therapy without the inconvenience of inflammatory side effects.

Figure 3
Proposed bidirectional Tet-Off regulatable adenovector expressing a fluorescent form of TK and the antiinflammatory peptide thymulin (FTS)
Figure 4
Differential length of expression for adenovirally delivered genes for thymulin, GFP and β-gal in the rat brain

POTENTIAL OF SUICIDE GENE THERAPY FOR THE TREATMENT OF HUMAN PITUITARY TUMORS

The development of gene therapy approaches for pituitary tumors is still incipient. While some of these approaches have already generated a core of results that emerge as a promising area of research for the treatment of pituitary tumors, no clinical trials have yet been documented. We are aware of only one gene therapy study using human pituitary cells. In this study, primary cultures of human lactotroph adenoma cells were successfully transduced with an adenoviral vector harboring the cDNA for human TH. The transduced cells not only expressed immunocytochemically-detectable TH, but were also shown to release significant levels of L-DOPA and dopamine which markedly reduced PRL release to the culture medium [61].

As already indicated, pituitary tumors seldom generate distant metastases. Although this feature allows the surgeon to spare normal pituitary tissue without the risk of tumor cell dissemination, neoplastic cells infiltrating the normal pituitary parenchyma may give rise to tumor regrowths. As mentioned before, pituitary tumor surgery is usually complemented with radiotherapy but, although this therapeutic combination is often effective to prevent tumor regrowth, it usually causes hypopituitarism due to excessive destruction of the normal pituitary parenchyma [62]. In this context, gene therapy appears to be a potentially superior alternative to radiotherapy for the treatment of pituitary tumors. In effect, after tumor removal, intrasurgical injection of an appropriate suicide vector into the spared pituitary parenchyma could achieve complete elimination of remaining tumor cells without affecting healthy cells. (Fig. 5). This therapeutic combination for the treatment of pituitary tumors has already been proposed [63].

Figure 5
Schematic representation of a possible application of suicide gene therapy to complement surgical treatment of pituitary tumors

EXPERT COMMENT

Although gene therapy requires further investigation of its efficiency and safety before it can be used for the treatment of pituitary diseases in humans, the versatility of this technique offers unique possibilites for the development of new therapeutic tools for a wide range of applications. These include tumor regression, supplementation of abnormal genes and normalization of hormone secretion. When pituitary tumors do not respond to current therapeutic strategies, pharmacological therapy is not well tolerated or the tumor becomes aggressive or difficult to treat over time, gene therapy could be an attractive treatment modality. Carefully designed and controlled clinical trials may assess the potential of gene therapy as a useful treatment option for currently difficult-to-treat pituitary tumors such as Cushing’s or non-secreting macroadenomas.

Combining current treatments, particularly surgery, with gene therapy could potentiate the efficacy of the former and provide long-term remission and even cure for many types of pituitary tumors. Although the field will need to advance further before gene therapy may become a routine treatment for human pituitary tumors, it remains as a promising therapeutic approach for the treatment of pituitary adenomas and tumors located in the sella turcica.

FIVE YEAR PROSPECT

Possibly, the most important issue that will have to be dealt with in the next five years, before suicide gene therapy may be routinely used for the treatemnt of human pituitary tumors, is adenovector-induced inflammation. As in other organs, adenoviral vectors have been shown to cause inflammation in the pituitary gland, an adverse effect that could be prevented by using bidirectional viral vectors expressing the gene for HSV-1 TK and the gene for an antiinflamatory peptide like thymulin (see main text).

Alternatively, the use of less immunogenic viral vectors, like the adeno-associated viral vectors, could be considered for the treatment of pituitary tumors. It should also be pointed out that, although so far only the HSV1-TK-GCV suicide system has been used to implement destructive experimental gene therapy of pituitary tumors, other available toxic systems might offer advantages over the TK-GCV system. Thus, studies with recombinant Ad vectors harboring cDNAs for three toxic genes, namely those encoding the HSV1-TK, the E. coli cytosine deaminase and the deoxycytidine kinase, showed that cytosine deaminase had the highest efficacy to reduce the growth of different human lung carcinoma cell lines [64].

Antisense and dominant negative gene therapies may constitute alternative strategies for the treatment of pituitary tumors. Suppression of endogenous basic fibroblast growth factor (bFGF) expression by means of an Ad vector carrying an antisense transgene for bFGF caused inhibition of the proliferation of human glioma cells. The same effect was achieved by means of an Ad vector carrying a transgene for a dominant negative FGF receptor [65].

Key issues

  • Pituitary adenomas constitute the most frequent neuroendocrine pathology in humans.
  • Current therapies for pituitary tumors have shown a significant degree of success but in general, are neither devoid of unwanted side effects nor offer a permanent cure.
  • The development of gene therapy approaches for the treatment of pituitary tumors emerges as a novel interventive startegy.
  • Intrasurgical gene therapy using adenovectors expressing the suicide gene for thymidine kinase appears as promising adjunt treatment to nonradical surgical removal of pituitary tumors.
  • Inflammation remains the most significant limitation of adenovirally-mediated suicide gene therapy of pituitary tumors, an adverse effect that could be prevented by using bidirectional viral vectors expressing the gene for TK and the gene for an antiinflamatory peptide, like thymulin.

Footnotes

Financial disclosure

Part of the studies reviewed here were supported by grants 11/M121 from from the University of La Plata and CICPBA to GMC, grant R01AG029798-2-A1 from the Fogarty International Center and the National Institute on Aging, NIH to RGG. RGG and GMC are CONICET and CIC-PBA career researchers, respectively.

References

1. Melmed S. Mechanisms of pituitary tumorigenesis: the plastic pituitary. J Clin Invest. 2003;112:1603–1618. [PMC free article] [PubMed]
2. Burek JD. Pathology of aging rats. CRC Press; Boca Raton, FL, USA: 1978.
3. Monson JP. The epidemiology of endocrine tumours. Endocr Relat Cancer. 2000;7:29–36. [PubMed]
4. Arafah BM, Nasralllah MP. Pituitary tumors: pathophysiology, clinical manifestations and management. Endocr Relat Cancer. 2001;8:287–305. [PubMed]
5. Swensen R, Kirsch W. Brain neoplasms in women: a review. Clin Obstet Gynecol. 2002;45:904–927. [PubMed]
6* Melmed S, Kleinberg D. Anterior pituitary. In: Kornenberg HM, Melmed S, Polonsky KS, Larsen PR, editors. Williams Textbook of Endocrinology. 11. Saunders – Elsevier; Philadelphia, PA, USA: 2008. pp. 155–261. Authoritative and updated review on the pituitary gland, its tumors and current treatments.
7. Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB. Diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab. 2005;90:3089–3099. [PubMed]
8. Shimon I, Melmed S. Management of pituitary tumors. Annals Int Med. 1998;129:472–483. [PubMed]
9. Melmed S. General aspects of the management of pituitary tumors by surgery or radiation therapy. In: DeGroot LJ, editor. Endocrinology. Saunders; Philadelphia, USA: 1997. pp. 497–503.
10. Sudhakar N, Ray A, Vafidis JA. Complications after transsphenoidal surgery: our experience and a review of the literature. Br J Neurosurg. 2004;18:507–512. [PubMed]
11. Serri O, Chik CL, Ur E, Ezzat S. Diagnosis and management of hyperprolactinemia. CMAJ. 2003;169:575–581. [PMC free article] [PubMed]
12. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med. 1994;331:904–909. [PubMed]
13. Sheppard MC. Aims of treatment and definition of cure. In: Wass JAH, editor. Treating Acromegaly-100 Years On. Society for Endocrinology; Bristol, UK: 1994. pp. 17–31.
14. Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev. 1992;13:220–240. [PubMed]
15. Sutton ML. Adult central nervous system. In: Easson EC, Pointon RCS, editors. The Radiotherapy of Malignant Disease. Springer; New York, USA: 1985. pp. 215–236.
16. Grigsby PW, Sheline GE. Pituitary. In: Perez CA, Bray LA, editors. Principles and Practice of Radiation Oncology. Lippincott; Philadelphia, USA: 1990. pp. 564–582.
17. Laws ER, Sheehan JP, Sheehan JM, Jagnathan J, Jane JA, Jr, Oskouian R. Stereotactic radiosurgery for pituitary adenomas: a review of the literature. J Neurooncol. 2004;69:257–272. [PubMed]
18. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 1997;275:1320–1323. [PubMed]
19. Hidaka C, Milano E, Leopold PL, Bergelson JM, Hackett NR, Finberg RW, et al. CAR - dependent and CAR-independent pathways of adenovirus vector - mediated gene transfer and expression in human fibroblast. J Clin Invest. 1999;103:579–587. [PMC free article] [PubMed]
20* Hitt M, Bett AJ, Addison CL, Prevec L, Graham FL. Techniques for human adenovirus vector construction and characterization. Meth Mol Gen. 1995;7:13–30. A comprehensive description of adenoviral vector construction principles.
21. Yang Y, Nunes FA, Berencsi K, Furth EE, Gonczol E, Wilson JM. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA. 1994;91:4407–4411. [PubMed]
22* Park JS, Chen L, Anton M, Sankar U, Rudnicki MA, Graham FL. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA. 1996;93:13565–13570. A comprehensive description of helper-dependent adenoviral vector construction principles. [PubMed]
23. Parks RJ, Graham FL. A helper-dependant system for adenovirus vector production helps define a lower limit for efficient DNA packaging. J Virol. 1997;71:3293–3298. [PMC free article] [PubMed]
24. Ideguchi M, Kajiwara K, Yoshikawa K, Uchida T, Ito H. Local adenovirus-mediated CTLA4-immunoglobulin expression suppresses the immune responses to adenovirus vectors in the brain. Neuroscience. 2000;95:217–226. [PubMed]
25. Geddes BJ, Harding TC, Hughes DS, Byrnes AP, Lightman SL, Conde G, et al. Persistent transgene expression in the hypothalamus following stereotaxic delivery of a recombinant adenovirus: suppression of the immune response with cyclosporin. Endocrinology. 1996;137:5166–5169. [PubMed]
26. Ilan Y, Prakash R, Davidson A, Jona V, Droguett G, Horwitz MS, et al. Oral tolerization to adenoviral antigens permits long-term gene expression using recombinant adenoviral vectors. J Clin Invest. 1997;99:1098–1106. [PMC free article] [PubMed]
27. Roizman B. The function of herpes simplex virus genes: a primer for genetic enginneering of novel vectors. Proc Natl Acad Sci USA. 1996;93:11307–11312. [PubMed]
28. Wolfe D, Goins WF, Yamada M, Moriuchi S, Krisky DM, Oligino TJ, et al. Engineering Herpes Simplex virus vectors for CNS applications. Exp Neurol. 1999;159:34–46. [PubMed]
29* Tomasec P, Bain D, Castro MG, Preston CM, Lowenstein PR. Herpes simplex virus temperature-sensitive mutant tsK as a vector for neuronal gene transfer. In: Lowenstein PR, Enquist LW, editors. Protocols for gene transfer in neuroscience: Towards gene therapy of neurological disorders. Wiley; Chichester, UK: 1996. pp. 169–186. A review on herpes-derived vectors used for experimental pituitary tumors.
30. Blesch A. Lentiviral and MLV based retroviral vectors for ex vivo and in vivo gene transfer. Methods. 2004;33:164–172. [PubMed]
31. Vogel R, Amar L, Thi AD, Saillour P, Mallet J. A single lentivirus vector mediates doxycycline-regulated expression of transgenes in the brain. Hum Gene Ther. 2004;15:157–165. [PubMed]
32** Li Z, Dullmann J, Schiedlmeier B, Schmidt M, von Kalle C, Meyer J, et al. Murine leukemia induced by retroviral gene marking. Science. 2002;296:497. Important article on the oncogenic potential of retroviral vectors. [PubMed]
33. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet. 2003;4:346–358. [PubMed]
34* Castro MG, Goya RG, Sosa YE, Rowe J, Larregina AT, Morelli AE, et al. Expression of transgenes in normal and neoplastic anterior pituitary cells using recombinant adenoviruses: long term expression, cell cycle dependency, and effects on hormone secretion. Endocrinology. 1007;138:2184–2194. First report on gene transfert in pituitary cells. [PubMed]
35. Goya RG, Rowe J, Sosa YE, Tomasec P, Lowenstein PR, Castro MG. Use of recombinant herpes simplex virus type I vectors for gene transfer into tumour and normal anterior pituitary cells. Molec Cell Endocrinol. 1998;139:199–207. [PubMed]
36* Davis JR, McMahon RF, Lowenstein PR, Castro MG, Lincoln GA, McNeilly AS. Adenovirus_mediated gene transfer in the ovine pituitary gland is associated with hypophysitis. J Endocrinol. 2002;173:265–271. A relevant report on the inflammatory side effects of adenoviral vectors in the pituitary gland. [PubMed]
37. Lee EJ, Thimmapaya B, Jameson JL. Stereotactic injection of adenoviral vectors that target gene expression to specific pituitary cell types: Implications for gene therapy. Neurosurgery. 2000;46:1461–1469. [PubMed]
38* Bolognani F, Albariño C, Romanowski V, Carri NG, Goya RG. In vitro and in vivo herpetic vector-mediated gene transfer in the pituitary gland: impact on hormone secretion. Eur J Endocrinol. 2001;145:497–503. A relevant report on the use of herpes-derived vectors for gene transfer in the pituitary gland.. [PubMed]
39. Carri NG, Sosa YE, Brown OA, Albarino C, Romanowski V, Goya RG. Studies on in vivo gene transfer in pituitary tumors using herpes-derived and adenoviral vectors. Brain Res Bull. 2005;65:17–22. [PubMed]
40. Roche C, Zamora AJ, Taieb D, Lavaque E, Rasolonjanahary R, Dufour H, et al. Lentiviral vectors efficiently transduce human gonadotroph and somatotroph adenomas in vitro. Targeted expression of transgene by pituitary hormone promoters. J Endocrinol. 2004;183:217–233. [PubMed]
41** Windeatt S, Southgate TD, Dewey RA, Bolognani F, Perone MJ, Larregina AT, et al. Adenovirus-mediated herpes simplex virus type-1 thymidine kinase gene therapy suppresses oestrogen-induced pituitary prolactinomas. J Clin Endocr Metab. 2000;85:1296–1305. A comprehensive study on suicide gene therapy in experimental pituitary tumors. [PubMed]
42. Lee EJ, Anderson LM, Thimmapaya B, Jameson JL. Targeted expresion of toxic genes directed by pituitary hormone promoters: a potential strategy for adenovirus-mediated gene therapy of pituitary tumors. J Clin Endocrinol Metab. 1999;84:786–794. [PubMed]
43** Southgate TD, Windeatt S, Smith-Arica J, Gerdes CA, Perone MJ, Morris I, et al. Transcriptional targeting to anterior pituitary lactotrophic cells using recombinant adenovirus vectors in vitro and in vivo in normal and estrogen/sulpiride-induced hyperplastic anterior pituitaries. Endocrinology. 2000;141:3493–3505. An important article on the use of transcriptional targeting in experimental rat pituitary tumors. [PubMed]
44* Southgate TD, Stone D, Williams JC, Lowenstein PR, Castro MG. Long-term transgene expression within the anterior pituitary gland in situ: Impact on circulating hormone levels, cellular and antibody-mediated immune responses. Endocrinology. 2001;142:464–476. An important study on the implementation of long-term gene therapy in experimental pituitary tumors. [PubMed]
45. Paquin A, Jaalouk DE, Galipeau J. Retrovector encoding a green fluorescent protein-herpes simplex virus thymidine kinase fusion protein serves as a versatile suicide/reporter for cell and gene therapy applications. Hum Gene Ther. 2001;12:13–23. [PubMed]
46* Cónsole G, Hereñú CB, Camihort GA, Luna GC, Bracamonte MI, Goya RG. Insulin like growth factor-I gene therapy reduces hyperprolactinemia and reverses morphologic changes in experimental rat prolactinomas. Mol Cancer. 2008;7:13–18. The first report on the implementation of IGF-I gene therapy in experimental pituitary tumors. [PMC free article] [PubMed]
47. Lee EJ, Jameson JL. Cell-specific Cre-mediated activation of the diphtheria toxin gene in pituitary tumor cells: potential for cytotoxic gene therapy. Hum Gene Ther. 2002;13:533–542. [PubMed]
48* Candolfi M, Jaita G, Pisera D, Ferrari L, Barcia C, Liu C, et al. Adenoviral vectors encoding tumor necrosis factor-alpha and FasL induce apoptosis of normal and tumoral anterior pituitary cells. J Endocrinol. 2006;189:681–90. A relevant study on the implementation of FasL gene therapy in pituitary tumor cell cultures. [PubMed]
49. Hu N, Gutsmann A, Herbert DC, Bradley A, Lee WH, Lee EY. Heterozygous Rb-1 delta 20/+mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance. Oncogene. 1994;9:1021–1029. [PubMed]
50. Riley DJ, Yu A, Lee WH. Adenovirus-mediated retinoblastoma gene therapy supresses spontaneous pituitary melanotroph tumors in Rb+/− mice. Nature Med. 1996;2:1316–1321. [PubMed]
51. Webster J, Ham J, Bevan J, Scalon M. Growth factors and pituitary tumors. Trends Endocrinol Metab. 1989;1:85–98. [PubMed]
52. Halper J, Parnel P, Carter B, Ren P, Scheithauer B. Presence of growth factors in human pituitary. Lab Invest. 1992;66:639–645. [PubMed]
53. Houben H, Denef C. Bioactive peptides in anterior pituitary cells. Peptides. 1994;15:547–582. [PubMed]
54. D’Ercole AJ, Stiles AD, Underwood LE. Tissue concentrations of somatomedin C: further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. Proc Natl Acad Sci USA. 1984;81:935–939. [PubMed]
55. Console GM, Hereñú CB, Camihort GA, Luna GC, Ferese C, Goya RG. Effect of insulin-like growth factor-I gene therapy on the somatotropic axis in experimental prolactinomas. Cells Tissues & Organs. 2009 in press. [PubMed]
56. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline responsive promoters. Proc Natl Acad Sci USA. 1992;88:5547–5551. [PubMed]
57** Smith-Arica JR, Williams JC, Stone D, Smith J, Lowenstein PR, Castro MG. Switching on and off transgene expression within lactotrophic cells in the anterior pituitary gland in vivo. Endocrinology. 2001;142:2521–2532. An important study on the use of regulatable viral vector for gene therapy in experimental pituitary tumors. [PubMed]
58. Williams JC, Stone D, Smith-Arica JR, Morris ID, Lowenstein PR, Castro MG. Regulated adenovirus-mediated delivery of tyrosine hydroxylase suppresses growth of estrogen-induced pituitary prolactinomas. Mol Ther. 2001;4:593–602. [PubMed]
59* Reggiani PC, Hereñú CB, Rimoldi OJ, Brown OA, Pléau JM, Dardenne M, et al. Gene therapy for long-term restoration of circulating thymulin in thymectomized mice and rats. Gene Ther. 2006;13:1214–1221. An important study on the use of the gene for the antinflammatory peptide thymulin in experimenal animals. [PubMed]
60. Morel GR, Brown OA, Reggiani PC, Hereñú CB, Portiansky EL, Zuccolilli GO, et al. Peripheral and mesencephalic transfer of a synthetic gene for the thymic peptide thymulin. Brain Res Bull. 2006;69:647–651. [PubMed]
61. Freese A, During MJ, Davidson BL, Gennarelli TA, Kaplitt MG, Flamm ES, et al. Transfection of human lactotroph adenoma cells with an adenovirus vector expressing tyrosine hydroxylase decreases prolactin release. J Clin Endocrinol Metab. 1996;81:2401–2404. [PubMed]
62. Littley MD, Shalet SM, Beardwell CG, Ahmed SR, Applegate G, Sutton ML. Hypopituitarism following external radiotherapy for pituitary tumours in adults. Q J Med. 1991;70:145–160. [PubMed]
63. Castro MG, Southgate T, Lowenstein PR. Molecular therapy in a model of neuroendocrine disease: developing clinical gene therapy for pituitary tumours. TEM. 2001;12:58–64. [PubMed]
64. Hoganson DK, Batra RK, Olsen JC, Boucher RC. Comparison of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma. Cancer Res. 1996;56:1315–1323. [PubMed]
65. Aoki T, Kato S, Fox JC, Okamoto K, Morimatsu M, Shigemori M. Inhibition of autocrine fibroblast growth factor signaling by the adenovirus-mediated expression of an antisense transgene or a dominant negative receptor in human glioma cells. Int J Oncol. 2002;21:629–636. [PubMed]
66. Goya RG, Sarkar DK, Brown OA, Hereñú CB. Potential of gene therapy for the treatment of pituitary tumors. Curr Gene Ther. 2004;4:79–87. [PMC free article] [PubMed]